Cerebral autoregulation issues in POTS even when CO₂ is normal
Ocon and colleagues published a 2009 study in the American Journal of Physiology that complicates — in a productive way — the picture that emerges from research emphasizing CO₂ and hyperventilation as the primary driver of orthostatic cerebral hypoperfusion in POTS. Their finding was direct: POTS patients who did not hyperventilate and whose CO₂ levels remained in the normal range during orthostatic challenge still showed impaired cerebral blood flow velocity and abnormal cerebrovascular regulation. The chemistry was fine. The regulation was not. This distinction has significant diagnostic and mechanistic consequences that most clinical evaluations miss entirely.
What Cerebral Autoregulation Is and Why It Fails in Some POTS Patients
Cerebral autoregulation is the brain's homeostatic mechanism for maintaining constant blood flow across a range of perfusion pressures. In a healthy individual, when systemic blood pressure fluctuates — as it does with every posture change — the cerebral vasculature responds dynamically. If perfusion pressure drops, cerebral arterioles dilate to maintain flow. If it rises, they constrict to prevent excess pressure from reaching the capillary bed. This regulation operates continuously and largely automatically, keeping cerebral blood flow within a narrow range despite significant changes in upstream pressure.
Dynamic autoregulation — the speed and efficiency of this response — is the relevant variable in orthostatic challenge. When a person stands, there is a brief gravitational redistribution of blood away from the thorax and head. The autoregulatory response compensates rapidly in healthy individuals, restoring cerebral blood flow within seconds. In POTS patients with impaired dynamic autoregulation, that compensatory response is delayed, blunted, or both. The cerebral vasculature does not dilate fast enough or sufficiently, and cerebral blood flow falls during the window when the compensation should have already occurred.
Crucially, this process is independent of CO₂ levels. CO₂ is a potent cerebrovascular dilator — even small reductions in CO₂ cause significant cerebral vasoconstriction. But the autoregulatory mechanism that responds to perfusion pressure changes is a separate system. A POTS patient can have perfectly normal CO₂ and still have impaired dynamic autoregulation. The Ocon paper demonstrated that this scenario is not hypothetical — it occurs in a real patient population and produces measurable reductions in cerebral blood flow velocity during tilt.
The Study Design: Separating CO₂ Effects From Autoregulatory Effects
The methodological value of this paper comes from the fact that it specifically studied POTS patients in the normocapnic subgroup — those who did not hyperventilate and whose end-tidal CO₂ remained normal. By focusing on this population, the researchers could attribute the observed cerebral blood flow changes to autoregulatory dysfunction rather than CO₂-mediated vasoconstriction. The two mechanisms were cleanly separated.
The measurement tool was transcranial Doppler ultrasonography, which provides a continuous, noninvasive readout of cerebral blood flow velocity in the middle cerebral artery. This is the same technology used in other important POTS cerebrovascular studies. The patients in the normocapnic POTS group showed lower cerebral blood flow velocity responses during tilt and evidence of impaired dynamic autoregulatory gain compared to healthy controls. Their brains were not regulating flow correctly despite a normal chemical environment for doing so.
The vasovagal syncope group in the same study showed a different pattern, consistent with the broader literature showing that these two conditions, often conflated in clinical settings, have distinct physiological profiles.
Two Mechanisms, One Outcome: Why Both Need to Be Measured
The practical consequence of this research is that CO₂ monitoring and cerebral blood flow velocity measurement are measuring different things, and both are necessary for a complete picture of what is happening in any given POTS patient during orthostatic challenge.
CO₂ monitoring — end-tidal capnography during tilt — tells you whether the patient is hyperventilating and whether that hyperventilation is driving cerebral vasoconstriction through hypocapnia. This is the mechanism documented since at least 1998. It is real and it is important. But it is not the complete story.
Transcranial Doppler monitoring tells you whether cerebral blood flow velocity is actually maintained during the challenge, independent of what CO₂ is doing. A patient with normal CO₂ and impaired autoregulation will show low cerebral blood flow velocity despite the absence of hypocapnia. A clinician who checks CO₂, sees a normal value, and concludes that cerebral perfusion must be fine has answered one question correctly and left the more fundamental question unasked.
This is not a theoretical concern. It has direct implications for how patients get evaluated and whether their cerebrovascular symptoms are attributed to something measurable or dismissed as unexplained. If the only tool available in the room is a blood pressure cuff and a heart rate monitor, neither the CO₂ mechanism nor the autoregulatory mechanism is visible. Both require different measurement approaches than what most standard tilt table evaluations include.
What Impaired Autoregulation Looks Like From the Inside
Patients with impaired dynamic cerebral autoregulation who do not hyperventilate may be particularly difficult to identify through standard evaluation because neither CO₂ nor blood pressure changes in ways that flag the problem. Heart rate rises. Blood pressure holds or compensates. CO₂ is normal. The clinical picture looks unremarkable on the parameters being measured. But the brain is not getting adequate flow because the regulatory system tasked with compensating for posture-related pressure changes is not doing its job at the required speed or magnitude.
The symptoms produced by this mechanism are functionally identical to symptoms produced by the CO₂ mechanism: lightheadedness, cognitive slowing, visual changes, head pressure, fatigue, difficulty thinking clearly while upright. The symptom profile does not distinguish between the two mechanisms. Only the measurement does.
This also matters for treatment. Interventions targeting CO₂ normalization — breathing retraining, pacing physical activity to prevent overbreathing — are specifically relevant for the hyperventilation-mediated subgroup. They address a mechanism that does not apply to the normocapnic autoregulatory subgroup. Volume expansion, physical reconditioning, and strategies to improve venous return address the hemodynamic inputs to the autoregulatory system and are more relevant for patients whose cerebral hypoperfusion is autoregulatory in origin.
The Diagnostic Gap This Paper Exposes
If you have had a tilt table test that showed POTS by heart rate criteria, and you have been told that everything else looked normal because your blood pressure held and you were not found to be hyperventilating, the Ocon paper is directly relevant to your situation. It documents a patient population that looks normal on the standard metrics — blood pressure maintained, CO₂ normal — and still has measurable, physiologically significant cerebral blood flow impairment on direct measurement.
The key word is direct. Cerebral blood flow velocity is not inferred from blood pressure or CO₂. It is measured, with a probe on the temporal bone, tracking flow in the middle cerebral artery in real time. That measurement is not a standard component of most POTS evaluations. Its absence does not mean cerebral perfusion was assessed and found normal. It means cerebral perfusion was not assessed at all.
What you now know is that the two primary mechanisms producing orthostatic cerebral hypoperfusion in POTS — hypocapnic vasoconstriction and impaired dynamic autoregulation — are independent, require different measurements to detect, and may respond to different interventions. A normal CO₂ reading does not close the cerebral perfusion question. It closes one chapter of it.